Have you or your loved ones been diagnosed with stage iii bladder urothelial carcinoma ajcc v6 and v7?

You may be eligible to participate in a stage iii bladder urothelial carcinoma ajcc v6 and v7 clinical trial.

Have you or your loved ones been diagnosed with stage iii bladder urothelial carcinoma ajcc v6 and v7? You may be eligible to participate in a stage iii bladder urothelial carcinoma ajcc v6 and v7 clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 Clinical Trial in Los Angeles CA
NCT02496208 | Phase 1 | Interventional

Have you or your loved ones been diagnosed with stage iii bladder urothelial carcinoma ajcc v6 and v7?

You may be eligible to participate in a stage iii bladder urothelial carcinoma ajcc v6 and v7 clinical trial.

Have you or your loved ones been diagnosed with stage iii bladder urothelial carcinoma ajcc v6 and v7? You may be eligible to participate in a stage iii bladder urothelial carcinoma ajcc v6 and v7 clinical trial.

Active not recruiting

Male & Female

18 Years +

This study is looking to recruit 152 Participants

This phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread to other places in the body (metastatic). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving cabozantinib s-malate and nivolumab alone or with ipilimumab works better in treating patients with genitourinary tumors.